Clinical Education update and Digestive Disease Week conference round-up

International ‘Pioneer’ super courses accelerating Creo’s SSD education. Key industry meeting bringing together physicians, researchers and industry

DDW 2022, the world’s premier meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, was the first in-person DDW event in two years and was attended by over 8,600 delegates in person, and 2,800 virtually. The Creo team hosted an exhibition stand to showcase the Company’s products, using this as a platform to network with industry experts. CEO Craig Gulliford, CTO Prof. Chris Hancock and CCO David Woods, supported by the Company’s global sales leadership team, were in attendance in San Diego to meet with existing and potential new customers as well as demonstrating Creo’s products and technologies.

 

Clinical Education Training

As a precursor to the DDW event, Creo held a Pioneer clinical training laboratory at the University of California San Diego on Friday 20 May. The Pioneer training laboratory brought together doctors from around the world to receive training on current and upcoming Creo products.

One attendee, Kenneth J. Chang, MD, MASGE, UCI Health, Founding Board Member, American Foregut Society (AFS) and winner of the prestigious ASGE Master Endoscopist Crystal Award 2022 commented:

There are many companies coming into the endoscopy space because the technology is growing so rapidly, but when I look at Creo as a company, I see a very strong commitment to safety, I see a company that is leveraging unique and distinct types of energy that allow for efficiency and safety. I see a commitment to training the physician through all the various stages in their journey to expertise. And I see a company that is really addressing our pain points, and the clinical needs that we have, and through innovation really expand our devices to address those pain points.

The past few months have seen Creo accelerate its recently branded ‘Pioneer’ training programme to reach more clinicians. Having previously managed to forge an excellent reputation for training, mentoring, and supporting clinicians, post-covid international freedoms have seen this programme shift up several gears. In addition to hosting training events in countries local to interested physicians, the Pioneer Programme includes ‘super courses’ where numerous doctors from across the world meet in premier training forums in order to guide more clinicians in the use of Creo’s Speedboat Inject device and the Speedboat Submucosal Dissection procedure.

Notable examples have been the first such course at the CREBA facility in Lleida, Spain – in which 13 doctors from Israel, Chile, Spain and elsewhere joined some Speedboat Injects’ most prominent users worldwide for two-days of intensive training.  On [date], clinicians from India, France, South Africa and the UK took part in another hugely successful international clinical training event In Cambridge, UK simultaneously with a comprehensive hands-on training lab in La Jolla, California, demonstrating not only the breadth of Creo’s training capability but also the growing worldwide interest in Creo’s innovative technology.

Feedback from recent trainees on the programme has been overwhelmingly positive, for example:

There are very few courses that offer this level of hands-on training and the kind of expertise where you get to meet people who were directly involved in the development of the technology. Dr Vanja Giljaca, UK

Further Super courses have already been booked in 2022 in EMEA and Creo also intends to widen its reach further in 2023 with joint US/EMEA courses to globally share its worldwide Speedboat Inject user experience.

Craig Gulliford, CEO, Creo Medical Group, said:

It was great to be able to attend this year’s Digestive Disease Week in San Diego in person for the first time since the pandemic. I am further encouraged by the reaction of industry experts to our game-changing technology, which we believe has the potential to improve patient outcomes all over the world. DDW allows us to showcase our products and network with key clinicians from around the world, which has led to a substantial number of new business opportunities for the Company.

The expansion and success of Creo’s training programme further validates the investment we have made in people and our facilities over the last 18 months.  To be able to introduce wider groups of clinicians to Creo’s unique technology with hands on didactic training not only enables wider collaboration within our user community but assists Creo to achieve its simple goal of improving lives.

Posted 06/27/22

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read

25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months

Read

12 September 2023

Half Year Report: H1-2023

Read

19 June 2023

Speedboat Inject cleared for upper GI use in Europe

Read

01 June 2023

Speedboat™ Inject selected by NICE for assessment

Read